Quantum Biopharma Ltd. amended its earlier report tied to registration number 333-276264, with the amendment stating that no other changes were made. Investors therefore have a limited update: the initial report remains effective except where later documents or reports supersede it.

Key Highlights

  • Quantum Biopharma identifies itself as a foreign private issuer.
  • The amendment says it forms part of the initial report from the date it was originally furnished, except where later documents supersede it.
  • Quantum Biopharma Ltd. amended an earlier regulatory report.
  • The amendment is identified as Amendment No. 1.

Quantum Biopharma Ltd. (NASDAQ: QNTM) amended an earlier regulatory report tied to registration number 333-276264, while leaving the rest of the initial report unchanged. The update is identified as Amendment No. 1.

Amendment Keeps Earlier Report Intact

The amendment states that it applies to the earlier report from the date that report was originally furnished. Its provisions remain subject to any later documents or reports that supersede the initial material. Quantum Biopharma signed the report on its own behalf through an authorised representative. The company identifies itself as a foreign private issuer and lists its principal executive offices in Toronto, Ontario.